Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

1
Player Avatar JohnT106 (54.62) Submitted: 3/8/2013 8:59:03 AM : Outperform Start Price: $1.41 PPHM Score: -11.72

Peregrine is advancing two novel cancer drug candidates that, combined with its hybrid business model, present attractive risk-reward opportunities in our view. Lead candidate bavituximab (bavi') has recently endured negative news flow, increasing skepticism from investors but creating a potential buying opportunity

Featured Broker Partners


Advertisement